Reference number(s)
2282-H

SPECIALTY QUANTITY LIMIT PROGRAM

IMBRUVICA (ibrutinib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	FDA-recommended dosing	Standard Limit
Imbruvica (ibrutinib) 70 mg capsules	**Mantle Cell Lymphoma and Marginal Zone Lymphoma:** 560 mg orally once daily until disease progression or unacceptable toxicity **Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Waldenström's Macroglobulinemia:** 420 mg orally once daily until disease progression or unacceptable toxicity **Chronic Graft versus Host Disease (cGVHD):** 420 mg orally once daily until cGVHD progression, recurrence of an underlying malignancy, or unacceptable toxicity Hepatic impairment (Child-Pugh class B): 70 mg to 140 mg orally daily Dose modifications due to adverse events or drug interactions: 70 mg to 420 mg orally once daily	30 per 30 days
Imbruvica (ibrutinib) 140 mg capsules		30 per 30 days
Imbruvica (ibrutinib) 140 mg tablets		30 per 30 days
Imbruvica (ibrutinib) 280 mg tablets		30 per 30 days
Imbruvica (ibrutinib) 420 mg tablets		30 per 30 days
Imbruvica (ibrutinib) 560 mg tablets		30 per 30 days

III. REFERENCES

1. Imbruvica [package insert]. Sunnyvale, CA: Pharmacyclics LLC; February 2018.

CVS caremark™